

Aubagne, September 30, 2022

## Sartorius Stedim Biotech completes acquisition of Albumedix

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has successfully closed the acquisition of Albumedix Ltd. as of September 30, 2022. Albumedix is a leader in the field of recombinant albumin-based solutions and based in Nottingham, UK.

This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. This is a translation of the original French-language press release. Sartorius Stedim Biotech shall not assume any liability for the correctness of this translation. The original French press release is the legally binding version.

### A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, the shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2021, the company employed more than 10,400 people, and earned sales revenue of around 2.89 billion euros.

### Contact

Philipp Grontzki

Head of External Communications

+49 (0)551.308.5581

[philipp.grontzki@sartorius.com](mailto:philipp.grontzki@sartorius.com)

Follow Sartorius Stedim Biotech on Twitter **@Sartorius\_Group** and on LinkedIn.